Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. - Wikidata - wikimedia - TriplyDB

Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression.

Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression.

http://www.wikidata.org/entity/Q33994367

about

Effectiveness and cost-effectiveness of antidepressants in primary care: a multiple treatment comparison meta-analysis and cost-effectiveness model Neuropsychologic effects of neuromodulation techniques for treatment-resistant depression: a review Noninvasive techniques for probing neurocircuitry and treating illness: vagus nerve stimulation (VNS), transcranial magnetic stimulation (TMS) and transcranial direct current stimulation (tDCS).Getting the balance right: Established and emerging therapies for major depressive disorders Risk of suicide during treatment with venlafaxine, citalopram, fluoxetine, and dothiepin: retrospective cohort study Bupropion: a systematic review and meta-analysis of effectiveness as an antidepressant Systematic Review of the Neurobiological Relevance of Chemokines to Psychiatric Disorders Challenging Treatment-Resistant Major Depressive Disorder: A Roadmap for Improved Therapeutics Pharmacological approaches to the challenge of treatment-resistant depression Efficacy, tolerability, and acceptability of bupropion for major depressive disorder: a meta-analysis of randomized-controlled trials comparison with venlafaxine Practical clinical trials in psychopharmacology: a systematic review Biochemical markers subtyping major depressive disorder Inhibitors of Fatty Acid Amide Hydrolase and Monoacylglycerol Lipase: New Targets for Future Antidepressants Emerging targets for antidepressant therapies Pharmacogenetic analysis of genes implicated in rodent models of antidepressant response: association of TREK1 and treatment resistance in the STAR(*)D study Treatment-resistant depression: critique of current approaches Rapid antidepressants stimulate the decoupling of GABA(B) receptors from GIRK/Kir3 channels through increased protein stability of 14-3-3η Midline and right frontal brain function as a physiologic biomarker of remission in major depression Mindfulness-based cognitive therapy (MBCT) versus the health-enhancement program (HEP) for adults with treatment-resistant depression: a randomized control trial study protocol.Identification and treatment of depression in minority populations.Modulation of early stress-induced neurobiological changes: a review of behavioural and pharmacological interventions in animal models.Extended-release bupropion: an antidepressant with a broad spectrum of therapeutic activity?Transcranial direct current stimulation for acute major depressive episodes: meta-analysis of individual patient data.Treatment-Resistant Depression Entering Remission Following a Seizure during the Course of Repetitive Transcranial Magnetic Stimulation.Long-term treatment of depression with antidepressants: a systematic narrative review.Telephone-based assessments to minimize missing data in longitudinal depression trials: a project IMPACTS study report Treatment-resistant depression and mortality after acute coronary syndrome.When is pharmacogenetic testing for antidepressant response ready for the clinic? A cost-effectiveness analysis based on data from the STAR*D study Fluoxetine and olanzapine combination therapy in treatment-resistant major depression: review of efficacy and safety data.Variation in the risk of suicide attempts and completed suicides by antidepressant agent in adults: a propensity score-adjusted analysis of 9 years' data A neurobiological hypothesis of treatment-resistant depression - mechanisms for selective serotonin reuptake inhibitor non-efficacy.The Impact of Residual Symptoms in Major Depression Diminished neural processing of aversive and rewarding stimuli during selective serotonin reuptake inhibitor treatment.Rationale and design of the randomised clinical trial comparing early medication change (EMC) strategy with treatment as usual (TAU) in patients with major depressive disorder--the EMC trial Treatment of depression: antidepressant monotherapy and combination therapy.Mechanisms underlying the antidepressant response and treatment resistance.The mistreatment of major depressive disorder.Optimized antidepressant therapy and pain self-management in primary care patients with depression and musculoskeletal pain: a randomized controlled trial Desvenlafaxine in major depressive disorder: an evidence-based review of its place in therapy.A systematic approach to pharmacotherapy for geriatric major depression

P2860

Q21134108-6DADDEE6-0ED0-4F2F-81EE-4174CADD1453 Q24594131-D6E3BE7B-8D3C-4731-B5DD-8942E7609E96 Q24602982-B209D553-EC30-4439-90A3-310C896AB656 Q24610225-F3052D61-7D4F-4C96-9868-55E00701C139 Q24678875-DAB273E0-0D98-4439-AA98-2CEB07EB9493 Q26747727-6DA30186-75F3-466F-A2C1-B7BBD75811CE Q26781639-1BE74C88-CCFE-4915-BF8F-D2A02811AC6C Q26782997-3068302B-348B-4541-9F50-B1113E1B6AE7 Q26798241-EB5AF345-C071-4680-9557-E2550F86D7AD Q26864531-E91A9027-BDE4-4F56-A192-977A39A263FC Q27021467-B275A454-2006-4F23-9F77-834E377F576F Q28081652-515638E4-E3EC-41F3-B9AB-35692350E48B Q28082891-45289F33-EBE2-4112-9177-E22625C15CA3 Q28247614-A3FB4C56-9EDE-45F5-A20E-4A86A9B0F395 Q28269390-424F4803-4B88-4116-BE13-23C269D43A38 Q28290605-14CAB8B9-F4B2-4C8A-8723-1D7E6D5B2890 Q28652455-ED12CA4C-5192-465D-91C2-B155B9E19549 Q29399995-759A724D-A2C2-45A0-9C2F-01C513EC7392 Q30360005-BC5F10C4-A89A-4A14-A338-74D42E1240CA Q30413593-37D14AB7-CD55-4D48-9CF0-AB1DF94931D6 Q30437906-138998A0-CAB4-474C-A3D2-CD01EAC63169 Q30442979-C37FEE74-74E7-4D0E-B34B-88E685CFDAD8 Q31071548-85A7E982-3BEB-4A99-819A-3223E6027A69 Q33167551-1A6252F5-A27A-4EEB-BC03-B3B0EE861484 Q33303427-0260356E-5731-4E44-B8B6-C0D2F4047BEF Q33365379-92AB6D35-6A99-4FF5-9A96-B7FA4B6F75B2 Q33418538-DF67CD0E-8669-4C61-83D7-2E1835889A3B Q33459789-E868AFCC-B06A-43F1-B2A2-8CACE3074441 Q33488312-64CD3B34-3C14-42BF-86C5-3BF8437B6F98 Q33571327-3199CF28-B8E2-42F6-8E40-9CB31B574D59 Q33658525-A356E7BC-1967-431C-B5C1-B724242959D8 Q33664080-D5E679EE-B483-4F7A-8903-ED0AFA4D308A Q33688119-C3FD197B-B6C1-4BDE-A279-23C9ED99E538 Q33724051-882354AA-490D-414F-9BF2-B244C6AEABEC Q33813998-4E80FDD2-77C9-4DB8-94D4-90A67C6CD8AE Q33814386-DF2F3C2C-1D82-4A33-A452-45C1A1013781 Q33836863-0EF710DA-9FC2-4966-80A6-AB9A11081B57 Q33908274-60E69869-5821-48AE-99E9-ED85A5D2529F Q33973909-D003C67C-B542-408B-AD84-637A7660A963 Q34004408-93D28BD2-2CDA-475A-8044-0DF9CE1C2D40

P2860

Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression.

http://www.wikidata.org/entity/Q33994367

description

2006 nî lūn-bûn

@nan

2006 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2006 թվականի մարտին հրատարակված գիտական հոդված

@hy

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

name

Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression.

@ast

Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression.

@en

type

label

Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression.

@ast

Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression.

@en

prefLabel

Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression.

@ast

Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression.

@en

P1433

Q33994367-BA35EAEF-50FD-480B-8DC3-CEC212F96949

P1476

Q33994367-57FFFDEB-1639-42D6-8788-1A6CDA0871EB

P2093

Q33994367-0946756C-D1A9-47F1-854B-E76BD6B2666B

Q33994367-0EF4924E-C95F-40EB-AD84-23CF5327277E

Q33994367-101B5463-9242-454B-B8D2-3243571201AE

Q33994367-38FAC528-A49D-4529-871C-CC81CC59999B

Q33994367-3ACAFDD4-CD39-48E9-9DF6-1C7E03ABDD29

Q33994367-3B01EBD2-2D7A-4E8D-9BD3-8234FCA12B48

Q33994367-3BA5C8D8-3C9A-41F1-96DA-CE55CB9459A1

Q33994367-45192FE4-ABBD-4DF8-80A8-DDD55FDE16D4

Q33994367-75E25D92-FE9F-4A8A-A02F-336098A06400

Q33994367-9087CF5F-CD56-460B-AB5C-3958B2D7B2E5

P304

Q33994367-EB05824B-387B-4B02-86A1-BFF4680E1186

P31

Q33994367-F95909E3-B7D1-47CA-B80F-9104D5F36E9C

P356

Q33994367-B18F7994-058C-4E47-A463-9B0ED84757FD

P407

Q33994367-1FA75902-8DC1-4F1D-AF82-29CCEB4C4DC5

P433

Q33994367-00B0D9F5-9D92-4F2B-97BA-706ED2525A59

P478

Q33994367-17449A4E-46C0-475E-BC7F-D4AC886ADDF1

P50

Q33994367-56631DBC-CC02-40F9-A844-38420FF294DA

Q33994367-D5C12332-13D3-47F3-9547-4131998E0B16

P577

Q33994367-28EBAEE9-F989-40BD-A5CA-951365BDBABB

P698

Q33994367-D963C0AA-C5B5-4652-8261-B56E11B7E7E5

P356

P1433

The New England Journal of Medicine

P1476

Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression

@en

P2093

Andrew A Nierenberg

http://www.w3.org/2001/XMLSchema#string

Diane Warden

http://www.w3.org/2001/XMLSchema#string

George Niederehe

http://www.w3.org/2001/XMLSchema#string

James F Luther

http://www.w3.org/2001/XMLSchema#string

Jonathan W Stewart

http://www.w3.org/2001/XMLSchema#string

Kathy Shores-Wilson

http://www.w3.org/2001/XMLSchema#string

Louise Ritz

http://www.w3.org/2001/XMLSchema#string

Madhukar H Trivedi

http://www.w3.org/2001/XMLSchema#string

Maurizio Fava

http://www.w3.org/2001/XMLSchema#string

Melanie M Biggs

http://www.w3.org/2001/XMLSchema#string

P304

1231-1242

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1056/NEJMOA052963

http://www.w3.org/2001/XMLSchema#string

P407

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

354

http://www.w3.org/2001/XMLSchema#string

P50

Augustus John Rush

Stephen R. Wisniewski

P577

2006-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

16554525

http://www.w3.org/2001/XMLSchema#string